| Name | Title | Contact Details |
|---|
Mission Statement The mission of American 1 Credit Union is to create financial wellness in our communities through personal everyday banking. From our beginning in 1950 to where we are today, serving over 62,000 people in five Michigan counties, American 1 Credit Union has been committed to providing excellent, low-cost everyday banking for our members. For more information on who we are, please visit - https://www.american1cu.org/about-us/who-we-are All loans are subject to approval. American 1 Disclosures - http://a1cu.us/Disclosures American 1 Privacy Policy - http://a1cu.us/Privacy-Policy This credit union is federally insured by the National Credit Union Administration. Equal Housing Opportunity. USA Patriot Act: Member Identification Requirements In accordance with Section 326 of the USA Patriot Act, applicants for new accounts are requested to provide current picture identification that verifies identity including name, address, and other identifying information. In some cases, identification will be requested for current members if original documentation was not obtained with the opening of the account. In all cases, protection of our members identity and confidentiality is our pledge to you. We proudly support all efforts to protect and maintain the security of our members and our country.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.